Correction
==========

In our study to evaluate the diagnostic accuracy of FENO measurement with NioxMino^®^for the diagnosis of asthma in general practice, we found the cut-off at FENO ≤ 12 ppb to rule out mild and moderate to severe asthma with a negative predictive value of 81% (95%CI 64--91%) \[[@B1]\]. We oriented ourselves at the already established value of 12 ppb \[[@B2]\]. However, we overlooked in the ROC analysis that the overall diagnostic accuracy improves slightly when the cut-off is chosen at FENO ≤ 16 ppb (revised table two) \[see table [1](#T1){ref-type="table"}\]. Negative likelihood ratio was 0.38 (95%CI 0.22--0.64) and positive likelihood ratio was 1.76 (95%CI 1.37--2.26) using the 16 ppb cut-off (revised table three) \[see Table [2](#T2){ref-type="table"}\].

###### 

Sensitivity (sens), specificity (spec), positive predictive value (PPV) and negative predictive value (NPV) at different cut-off points (n = 160); unit of FENO is parts per billion

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Asthma diagnoses**                                                                    **FENO**   **sens \[%\] (95%CI)**   **spec \[%\] (95%CI)**   **PPV \[%\] (95%CI)**   **NPV \[%\] (95%CI)**   **n**
  --------------------------------------------------------------------------------------- ---------- ------------------------ ------------------------ ----------------------- ----------------------- -------
  Borderline BHR mild BHR moderate to severe BHR positive bronchodilator reversibility\   \> 12      85 (76--92)              24 (16--34)              50 (41--58)             65 (47--79)             126
  (n = 75)\*                                                                                                                                                                                           

                                                                                          \> 16      69 (58--79)              53 (42--63)              57 (46--66)             66 (54--76)             92

                                                                                          \> 20      64 (53--74)              58 (47--77)              57 (47--67)             65 (53--74)             82

                                                                                          \> 35      32 (25--42)              84 (74--90)              63 (47--77)             58 (49--67)             38

                                                                                          \> 46      32 (23--43)              93 (85--97)              80 (63--91)             61 (52--69)             30

                                                                                          \> 76      13 (7--23)               100 (96--100)            100 (72--100)           57 (49--65)             11

                                                                                                                                                                                                       

  Mild BHR moderate to severe BHR positive bronchodilator reversibility\                  \> 12      90 (79--95)              25 (17--34)              40 (32--49)             81 (64--91)             126
  (n = 58)^§^                                                                                                                                                                                          

                                                                                          \> 16      79 (67--88)              55 (45--64)              50 (40--60)             82 (72--90)             92

                                                                                          \> 20      67 (54--78)              62 (52--71)              50 (39--61)             77 (67--85)             82

                                                                                          \> 35      36 (25--49)              83 (75--89)              55 (40--70)             70 (61--77)             38

                                                                                          \> 46      36 (25--49)              91 (84--95)              70 (52--83)             72 (63--79)             30

                                                                                          \> 76      17 (10--29)              100 (96--100)            100 (72--100)           68 (60--75)             11
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*prevalence of asthma = 46.9%, prevalence of \'no asthma\' = 53.1%

^§^prevalence of asthma = 36,3%, prevalence of \'no asthma\' = 63.7%

###### 

Likelihood ratio at different cut-off points (n = 160); unit of FENO is parts per billion; LR+ is positive likelihood ratio, LR- is negative likelihood ratio

  **Asthma diagnoses**                                                                               **FENO**   **LR+ (95%CI)**      **LR- (95%CI)**
  -------------------------------------------------------------------------------------------------- ---------- -------------------- -------------------
  Borderline BHR, mild BHR, moderate to severe BHR, positive bronchodilator reversibility (n = 75)   \> 12      1.12 (0.96--1.30)    0.62 (0.32--1.21)
                                                                                                     \> 16      1.47 (1.12--1.93)    0.58 (0.39--0.86)
                                                                                                     \> 20      1.55 (1.12--2.14)    0.65 (0.47--0.91)
                                                                                                     \> 35      1.94 (1.09--3.48)    0.81 (0.68--0.98)
                                                                                                     \> 46      4.53 (1.96--10.49)   0.73 (0.62--0.86)
                                                                                                     \> 76      not calculable       not calculable
                                                                                                                                     
  Mild BHR, moderate to severe BHR, positive bronchodilator reversibility (n = 58)                   \> 12      1.19 (1.03--1.37)    0.42 (0.18--0.97)
                                                                                                     \> 16      1.76 (1.37--2.26)    0.38 (0.22--0.64)
                                                                                                     \> 20      1.76 (1.30--2.39)    0.53 (0.36--0.79)
                                                                                                     \> 35      2.17 (1.25--3.77)    0.77 (0.62--0.95)
                                                                                                     \> 46      4.10 (2.02--8.36)    0.70 (0.57--0.86)
                                                                                                     \> 76      not calculable       not calculable

In patients with unsuspicious spirometric results (n = 101; not in table) there was no improvement of diagnostic accuracy. The best cut-off point was at FENO ≤ 16 ppb again. In this diagnostic group sensitivity was 78% (95%CI 63--89%), specificity was 45% (95%CI 34--57%), PPV was 45% (95%CI 34--57%) and NPV was 78% (95%CI 63--89%).

Table two \[see Table [1](#T1){ref-type="table"} below\] illustrates that the patient group with correctly excluded asthma by FENO measurement increases at FENO ≤ 16 ppb; and the range of the confidence interval narrows. Thus three patients need to be diagnosed for excluding asthma in order to save one bronchial provocation test when FENO ≤ 16 ppb is used as the cut-off point. With FENO ≤ 12 ppb five patients need to be tested in order to exclude asthma in one of them. Therefore, we suggest choosing FENO ≤ 16 ppb to rule out mild and moderate to severe asthma. This improves diagnostic efficiency compared to the ≤ 12 ppb cut-off point.

We would like to correct the following points in the manuscript:

In the **Results**section of the **Abstract**lines 6--7 should read as:

\"16 ppb (n = 68; 42.5%), sensitivity was 79% (95%CI 67--88), specificity 55% (95%CI 45--64), PPV 50% (95%CI 40--60), NPV 82% (95%CI 72--90)\".

Also in line 7, \"Three\" should say \"Two\".

In the **Conclusion**section of the **Abstract**, in line 2, \"FENO ≤ 12 ppb\" should say \"FENO ≤ 16 ppb\".

In the **Sensitivity analyses**section, in line 2 of the third paragraph, \"FENO ≤ 12 ppb\" should say \"FENO ≤ 16 ppb\", \"81% (95% CI 64--91)\" should say \"82% (95% CI 72--90)\" and \"34\" should say \"68\". In line 3, \"FENO ≤ 12 ppb\" should say \"FENO ≤ 16 ppb\" and \"five\" should say \"three\". In line 4 \"12 ppb\" should say \"16 ppb\". The sentence starting in line 5 and ending in line 6 should read: \"Sensitivity was 78% (95%CI 63--89), specificity was 45% (95%CI 34--57), PPV was 45% (95%CI 34--57), NPV was 78 (95%CI 63--89)\". In line 6, \"16 (15.8%)\" should say \"37 (36.6%)\", \"FENO ≤ 12 ppb\" should say \"FENO ≤ 16 ppb\" and \"increased up to 82% (95%CI 64--92)\" should say \"was 77% (95%CI 61--88)\".

In the **Discussion**section, in line 4, \"81%\" should say \"82%\" and in line 5, \"FENO ≤ 12\" should say \"FENO ≤ 16\"

In the second paragraph, in line 1, \"five\" should say \"three\". In line 5, \"16 patients had FENO ≤ 12 ppb\" should say \"37 patients had FENO ≤ 16 ppb\". Also in line 5, \"three\" should say \"two\" and in lines 11 and 12 \"FENO ≤ 12 ppb\" should say \"\"FENO ≤ 16 ppb\" and 12 ppb\<FENO should say 16 ppb\<FENO.

In the third line of the third paragraph \"12 to 46 ppb\" should say \"16 to 46 ppb\" and in the seventh line, the second half of the sentence that reads **\"**and the difference of the 95%CI (-9.8 ppb) and 20 ppb is close to our best cut-off point (12 ppb) to rule out asthma\" should not be there.

In the **conclusion**section, in line 3 \"FENO ≤ 12 ppb\" should say \"\"FENO ≤ 16 ppb\" and \"three\" should say \"two\".
